

Antonella De Luca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/364851/publications.pdf>

Version: 2024-02-01

93
papers

8,132
citations

101384

36
h-index

53109

85
g-index

96
all docs

96
docs citations

96
times ranked

11566
citing authors

#	ARTICLE	IF	CITATIONS
1	Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion. <i>Oncologist</i> , 2022, 27, 7-12.	1.9	3
2	The EGFR Signaling Modulates in Mesenchymal Stem Cells the Expression of miRNAs Involved in the Interaction with Breast Cancer Cells. <i>Cancers</i> , 2022, 14, 1851.	1.7	4
3	EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1653-1665.	1.3	8
4	Promising Role of Circulating Tumor Cells in the Management of SCLC. <i>Cancers</i> , 2021, 13, 2029.	1.7	7
5	FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6856.	1.8	67
6	Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management. <i>Cancers</i> , 2020, 12, 2914.	1.7	26
7	cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation?. <i>EBioMedicine</i> , 2020, 57, 102886.	2.7	1
8	Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls. <i>Cancers</i> , 2020, 12, 3804.	1.7	26
9	Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications. <i>Translational Lung Cancer Research</i> , 2020, 9, 61-70.	1.3	10
10	The potential of monitoring treatment response in non-small cell lung cancer using circulating tumour cells. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 683-694.	1.5	13
11	Extracellular matrix proteins as circulating biomarkers for the diagnosis of non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2019, 11, S1252-S1256.	0.6	7
12	Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. <i>Cancers</i> , 2019, 11, 859.	1.7	27
13	The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Cancers</i> , 2019, 11, 341.	1.7	52
14	Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC). <i>Oncotarget</i> , 2018, 9, 17554-17563.	0.8	21
15	The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. <i>Cancer Treatment Reviews</i> , 2018, 70, 1-8.	3.4	116
16	Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 891-900.	1.5	16
17	RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cells. <i>Oncotarget</i> , 2018, 9, 17543-17553.	0.8	22
18	FGFR-targeted therapeutics for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 303-311.	1.9	25

#	ARTICLE	IF	CITATIONS
19	Targeting the EGFR T790M mutation in non-small-cell lung cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 159-165.	1.5	28
20	VEGF as a potential target in lung cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 959-966.	1.5	159
21	Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer. Translational Lung Cancer Research, 2017, 6, 486-498.	1.3	43
22	Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. Oncotarget, 2016, 7, 66595-66605.	0.8	78
23	Vascular Endothelial Growth Factor A Regulates the Secretion of Different Angiogenic Factors in Lung Cancer Cells. Journal of Cellular Physiology, 2016, 231, 1514-1521.	2.0	39
24	The prognostic role of circulating tumor cells in lung cancer. Expert Review of Anticancer Therapy, 2016, 16, 859-867.	1.1	16
25	EGFR and MEK Blockade in Triple Negative Breast Cancer Cells. Journal of Cellular Biochemistry, 2015, 116, 2778-2785.	1.2	40
26	EGFR mutations in lung cancer: from tissue testing to liquid biopsy. Future Oncology, 2015, 11, 1611-1623.	1.1	82
27	Structure-fluctuation-function relationships of seven pro-angiogenic isoforms of VEGFA, important mediators of tumorigenesis. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 410-425.	1.1	14
28	Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1177-1185.	1.5	11
29	Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients. Pharmacogenomics, 2015, 16, 1135-1148.	0.6	26
30	Prognostic value of circulating tumor cells reduction in patients with extensive small-cell lung cancer. Lung Cancer, 2014, 85, 314-319.	0.9	56
31	Vandetanib as a potential treatment for breast cancer. Expert Opinion on Investigational Drugs, 2014, 23, 1295-1303.	1.9	10
32	Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib. Cell Cycle, 2014, 13, 148-156.	1.3	40
33	RNA-seq analysis reveals significant effects of EGFR signalling on the secretome of mesenchymal stem cells. Oncotarget, 2014, 5, 10518-10528.	0.8	16
34	Quercetin methyl ether inhibits lapatinib sensitive and resistant breast cancer cell growth by inducing G ₂ /M arrest and apoptosis. Molecular Carcinogenesis, 2013, 52, 134-143.	1.3	35
35	Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities. Journal of Cellular Biochemistry, 2013, 114, 514-524.	1.2	66
36	Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity. Journal of Cellular Biochemistry, 2013, 114, 1135-1144.	1.2	34

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetic evaluation of capecitabine in breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 225-235.	1.5	9
38	Detection of EGFR Mutations by TaqMan Mutation Detection Assays Powered by Competitive Allele-Specific TaqMan PCR Technology. <i>BioMed Research International</i> , 2013, 2013, 1-9.	0.9	32
39	Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 3363-3370.	1.2	92
40	Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. <i>Annals of Oncology</i> , 2012, 23, 597-604.	0.6	67
41	The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S17-S27.	1.5	580
42	Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 299-307.	1.1	5
43	Zoledronic acid in early-stage breast cancer. <i>Lancet Oncology</i> , 2011, 12, 991.	5.1	1
44	Pharmacokinetic evaluation of zoledronic acid. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 911-918.	1.5	13
45	Optimizing response to gefitinib in the treatment of non-small-cell lung cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2011, Volume 4, 1-9.	0.4	4
46	Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. <i>Journal of Cellular Physiology</i> , 2011, 226, 2131-2138.	2.0	91
47	Expression and functional role of CRIPTO-1 in cutaneous melanoma. <i>British Journal of Cancer</i> , 2011, 105, 1030-1038.	2.9	34
48	Abstract 3581: Characterization of human breast cancer cells with acquired resistance to the EGFR/ErbB-2 tyrosine kinase inhibitor lapatinib. , 2011, , .		1
49	Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer. <i>Current Drug Targets</i> , 2010, 11, 851-864.	1.0	46
50	Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 387-396.	1.1	39
51	23 ZOLEDRONIC ACID BLOCKS THE INTERACTION BETWEEN MESENCHYMAL STEM CELLS AND BREAST CANCER CELLS. <i>Cancer Treatment Reviews</i> , 2010, 36, S101-S102.	3.4	0
52	Effect of zoledronic acid acts on the interaction between mesenchymal stem cells and breast cancer cells within the bone microenvironment.. <i>Journal of Clinical Oncology</i> , 2010, 28, 10602-10602.	0.8	1
53	Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2009, 360, 679-691.	13.9	976
54	Prognostic Applications of Gene Expression Signatures in Breast Cancer. <i>Oncology</i> , 2009, 77, 2-8.	0.9	20

#	ARTICLE	IF	CITATIONS
55	Target-based therapies in breast cancer: current status and future perspectives. <i>Endocrine-Related Cancer</i> , 2009, 16, 675-702.	1.6	62
56	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 519-527.	12.5	391
57	A "live" biopsy in a small-cell lung cancer patient by detection of circulating tumor cells. <i>Lung Cancer</i> , 2009, 65, 123-125.	0.9	32
58	35LBA Zoledronic acid affects the ability of mesenchymal stem cells to sustain breast cancer progression. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 17.	2.2	0
59	Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.. , 2009, , .		2
60	Signal Transduction Inhibitors in the Treatment of Breast Cancer. , 2009, , 177-201.		0
61	Endocrine therapy plus zoledronic acid in premenopausal breast cancer. <i>New England Journal of Medicine</i> , 2009, 360, 2368-9; author reply 2369-70.	13.9	3
62	Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 25-33.	1.1	40
63	The role of the EGFR signaling in tumor microenvironment. <i>Journal of Cellular Physiology</i> , 2008, 214, 559-567.	2.0	323
64	Molecular biology of renal-cell carcinoma. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 30-34.	2.2	2
65	Expression and prognostic significance of the EGFR in solid tumors. , 2008, , 210-223.		1
66	Breast and Colon Carcinomas: Detection with Plasma CRIPTO-1. , 2008, , 189-202.		0
67	Erlotinib in Pancreatic Cancer: Are Tumor Cells the (only) Target?. <i>Journal of Clinical Oncology</i> , 2007, 25, 5836-5837.	0.8	6
68	AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. <i>Breast Cancer Research and Treatment</i> , 2007, 102, 275-282.	1.1	15
69	Epidermal growth factor receptor (EGFR) signaling in cancer. <i>Gene</i> , 2006, 366, 2-16.	1.0	1,744
70	The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. <i>Journal of Cellular Physiology</i> , 2006, 207, 420-427.	2.0	127
71	Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 5158-5164.	3.2	79
72	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 2611.	3.0	22

#	ARTICLE	IF	CITATIONS
73	Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?. <i>Annals of Oncology</i> , 2005, 16, 1709.	0.6	10
74	Modulation of Epidermal Growth Factor Receptor-Positive Circulating Tumor Cells by Chemotherapy in Non-Small-Cell Lung Cancer Patients. <i>Journal of Clinical Oncology</i> , 2005, 23, 7746-7748.	0.8	4
75	Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. <i>Endocrine-Related Cancer</i> , 2005, 12, 471-482.	1.6	93
76	The ErbB Receptors and their Ligands in Cancer: An Overview. <i>Current Drug Targets</i> , 2005, 6, 243-257.	1.0	257
77	Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. <i>Endocrine-Related Cancer</i> , 2005, 12, 721-747.	1.6	242
78	Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. <i>Journal of Cellular Physiology</i> , 2004, 198, 31-39.	2.0	61
79	Small Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: An Overview. <i>Journal of Chemotherapy</i> , 2004, 16, 36-40.	0.7	10
80	CRIPTO-1: a novel target for therapeutic intervention in human carcinoma. <i>International Journal of Oncology</i> , 2004, 25, 1013-20.	1.4	9
81	Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): Simple drugs with a complex mechanism of action?. <i>Journal of Cellular Physiology</i> , 2003, 194, 13-19.	2.0	124
82	Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.. <i>Endocrine-Related Cancer</i> , 2003, 10, 1-21.	1.6	279
83	Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. <i>Journal of Clinical Investigation</i> , 2003, 112, 575-587.	3.9	136
84	Transforming growth factor β , amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. <i>International Journal of Oncology</i> , 2002, 21, 941.	1.4	19
85	Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. <i>Annals of Oncology</i> , 2002, 13, 65-72.	0.6	240
86	Cripto-1 Activates Nodal- and ALK4-Dependent and -Independent Signaling Pathways in Mammary Epithelial Cells. <i>Molecular and Cellular Biology</i> , 2002, 22, 2586-2597.	1.1	139
87	Detection and localization of Cripto-1 binding in mouse mammary epithelial cells and in the mouse mammary gland using an immunoglobulin-cripto-1 fusion protein. <i>Journal of Cellular Physiology</i> , 2002, 190, 74-82.	2.0	20
88	The role of EGF-related peptides in tumor growth. <i>Frontiers in Bioscience - Landmark</i> , 2001, 6, d685.	3.0	141
89	EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells. <i>Annals of Oncology</i> , 2000, 11, 319-326.	0.6	33
90	Simultaneous blockade of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. <i>Oncogene</i> , 2000, 19, 5863-5871.	2.6	88

#	ARTICLE	IF	CITATIONS
91	EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. , 1999, 80, 589-594.		39
92	Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells.. Oncology Reports, 1999, 6, 1105-9.	1.2	26
93	Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells. , 1997, 73, 277-282.		35